Structure Therapeutics (GPCR) Free Cash Flow (2022 - 2026)

Structure Therapeutics' Free Cash Flow history runs 5 years deep, the most recent figure standing at $14.1 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 126.74% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at -$156.5 million (down 14.88% YoY), while the FY2025 annual figure was -$223.1 million, down 89.18% from the prior year.
• Free Cash Flow was $14.1 million for Q1 2026 at Structure Therapeutics, up from -$63.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $14.1 million in Q1 2026 to a low of -$63.2 million in Q4 2025.
• Historically, Free Cash Flow has averaged -$26.7 million across 5 years, with a median of -$20.7 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Free Cash Flow plunged 157.93% in 2025, then jumped 126.74% in 2026.
• A 5-year view of Free Cash Flow shows it stood at -$12.1 million in 2022, then plunged by 94.96% to -$23.6 million in 2023, then plunged by 54.69% to -$36.5 million in 2024, then sank by 73.21% to -$63.2 million in 2025, then soared by 122.24% to $14.1 million in 2026.
• The last three Free Cash Flow figures came in at $14.1 million (Q1 2026), -$63.2 million (Q4 2025), and -$52.6 million (Q3 2025), per Business Quant data.